SHAREHOLDER ALERT: Investigation on Behalf of Endocyte, Inc. Investors Announced by Law Offices of Howard G. Smith

BENSALEM, Pa.--(BUSINESS WIRE)--

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Endocyte, Inc. (“Endocyte” or the “Company”) ECYT. The investigation concerns possible violations of federal securities laws and focuses on the Company's business and financial prospects.

Endocyte is a biopharmaceutical company engaged in the development of targeted therapies for the treatment of cancer and inflammatory diseases. The investigation is related to Endocyte's May 2, 2014, disclosure that the Company's experimental drug VYNFINIT® was found ineffective in the treatment of platinum-resistant ovarian cancer, based on certain testing methods known as response evaluation criteria in solid tumors. The Company subsequently announced that it would withdraw its application to market VYNFINIT in Europe.

If you purchased Endocyte securities between March 21, 2014 and May 2, 2014, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at 215-638-4847, Toll-Free at 888-638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.